The sleep papers and their companions
The main trial, the later analyses, and the papers that put treatment burdens beside the overnight findings.
Start with the overnight studies
The main SURMOUNT-OSA report is the starting point for the breathing-event results. Read it beside the time-course and weight-association analysis, then the participant-reported sleep and quality-of-life paper.
These are related publications from the same trial program. The later reports add questions and analyses; they should not be counted as fresh, separate populations confirming the original result.
For the treatment-burden question
The SURMOUNT-1 obesity trial supplies the weight-management and gastrointestinal context used here. The gallbladder and pancreatitis meta-analysis addresses specific safety outcomes, while the wider safety review surveys tolerability and the remaining concerns across tirzepatide and GLP-1 receptor agonists.
The SURMOUNT-4 withdrawal trial is included for its weight findings. It belongs in the discussion of persistence, with the sleep-withdrawal question still open.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity ↗
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight. ↗
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. ↗
- Tirzepatide Once Weekly for the Treatment of Obesity ↗
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. ↗
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. ↗
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. ↗